Introduction {#S1}
============

Axonal transection and axon loss are common phenomena in multiple sclerosis (MS), which is a demyelinating disease in humans. Pathological characteristics of MS include progressive demyelination and neurological deterioration^\[[@R1]\]^. Pathogenesis in MS is associated with many unknown factors such as recurrent viral infection, heredity, autoimmune demyelination, etc.^\[[@R2],\ [@R3]\]^ Demyelination may proceed via different mechanisms in different MS patients^\[[@R4]\]^ due to its stimulation by a variety of factors such as proteolytic enzymes, cytokines, oxidative products, and free radicals^\[[@R4]\]^. It is evident that inflammatory cytokines play a critical role in pathogenesis in MS lesion in humans and animals^\[[@R5],\ [@R6]\]^ by triggering inflammation,^\[[@R6],\ [@R7]\]^ though the precise mechanism of cytokine action mostly remains unresolved. Immune cell filtration accompanying chronic inflammation signifies that MS is an autoimmune demyelinating disease in the central nervous system (CNS) although the precise etiology of MS has not yet been resolved^\[[@R8]\]^. However, there remain many major unanswered issues such as primary cause of inflammation, primary target antigen, stimulation of autoimmunity, etc.^\[[@R8]--[@R11]\]^ Sphingolipids including lysosphingolipids such as galactosylceramide (GalCer), ceramide, sphingoids (sphingosine or sphingenine and sphinganine), and psychosine are major components of myelin^\[[@R12]\]^. Based on studies in our laboratories, we have developed a hypothesis that sphingolipids and lysosphingolipids are metabolically altered in MS and the elevation of toxic lipids may cause apoptotic death or degeneration of oligodendrocytes and neurons.

Sphingolipids are critically involved during brain development as they stimulate cell growth, differentiation, myelinogenesis, and maintain the structural and functional integrity of the CNS and also the peripheral nervous system (PNS)^\[[@R12]--[@R14]\]^. Sphingolipid metabolism is highly regulated for normal development and function of both the CNS and PNS. Alterations in spatial and temporal levels of sphingolipids may severely compromise the maintenance of the functional integrity of the nervous system. Indeed, changes in the sphingolipid system have recently emerged as key factors in CNS disorders. An understanding of the alterations in the levels of sphingolipids and their signaling mechamism due to inflammatory responses in neurodegenerative diseases is essential in finding appropriate therapeutic agents for the treatment of these diseases. Because MS has a major inflammatory component in its pathogenesis, production and function of sphingolipids are highly affected in MS. Although the regulatory pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα), interferon-gamma (IFNγ), transforming growth factor-beta (TGF-β), interleukin-6 (IL-6), etc. have been implicated in fostering inflammation and demyelination in MS^\[[@R8],\ [@R15],\ [@R16]\]^, their mechanism of action via sphingolipid toxicity in MS has recently been reported^\[[@R17]\]^. Both TNFα and IFNγ are highly upregulated in MS brain and EAE tissues^\[[@R18],\ [@R19]\]^ and they act synergistically triggering induction of apoptosis in a wide variety of cells such as cardiomyocytes, oligodendrocytes, astroglia^\[[@R20]--[@R23]\]^. Notably, TNFα and IFNγ are elevated in MS patients after 8 weeks of endurance training^\[[@R24]\]^.

Recently published reports indicated alterations in sphingolipids in MS tissues^\[[@R25]--[@R27]\]^ and an earlier report suggested that sphingosine was elevated in MS brain^\[[@R28]\]^. A recent report^\[[@R29]\]^ and a publication from our laboratory confirmed elevation of sphingosine in MS brain^\[[@R17]\]^. Although a correlation between MS demyelination and oligodendrocyte cell death exists^\[[@R30]--[@R32]\]^ we have for the first time explored the kinetics of cytokine-mediated ceramide and sphingoid biosysthesis leading to oligodendrocyte death in MS^\[[@R17]\]^.

In this review article, we discuss the cytokine-mediated sphingosine elevation triggered by *de novo* ceramide biosynthesis via serine-palmitoyltransferase (SPT) activation in MS^\[[@R33]\]^. *In vivo* ceramide is ultimately metabolized to sphingosine, indicating that *de novo* ceramide production may be a potential therapeutic target for treatment of MS in the future.

SPT activation and ceramide/sphingosine generation for oligodendrocyte degeneration in MS brain {#S2}
===============================================================================================

We have hypothesized that aberrant sphingolipid metabolism in MS tissues may be responsible for oligodendrocyte cell death leading to demyelination. Oligodendrocytes may die in different pathological scenarios such as MS and adrenoleukodystrophy^\[[@R34]\]^ as well as in other neurodegenerative diseases^\[[@R35],\ [@R36]\]^. Moreover, significant abnormalities, such as water content, astrocytic and microglial proliferation, perivascular inflammation, and occasionally, demyelination have been identified in normal appearing white matter (NAWM) in MS patients by using magnetization transfer imaging^\[[@R37],\ [@R38]\]^. Degeneration in the NAWM is a significant feature of MS and it brings about disease progression and gradual disability in MS patients. Histopathological examination of NAWM in MS patients is known to agree with the concept that areas outside the plaques harbor pathological changes that contribute to disease progression. In fact, it is now widely acknowledged that microglial activation, T cell infiltration, and perivascular cuffing occur in NAWM in MS patients. Different studies have confirmed the existence of these features in progressive MS patients. Nowadays, it is beyond reasonable doubt that a significant involvement of NAWM in progressive MS contributes to the destructive inflammation that spreads beyond central lesion areas. In a nutshell, the extent of tissue degeneration and biochemical abnormalities in white matter and the pathological features in NAWM have to be taken seriously in defining progressive MS. Axon loss typifies degeneration in NAWM. Tissue alterations and biochemical changes in NAWM precede demyelination in MS. Biochemical changes such as perturbed sphingolipid metabolism in NAWM, as reported above, is in well agreement with physico-chemical studies and may have an important implication for the disease pathogenesis. In addition, an increase in sphingosine content in NAWM and plaque in MS tissues was in compliance with previous studies that examined the MS brain sphingolipid metabolism^\[[@R17],\ [@R28],\ [@R29]\]^. However, the mechanism of sphingosine accumulation and its effect on oligodendroglia have not yet been clearly understood until our recent report^\[[@R17]\]^.

Both ceramide and sphingosine accumulation in conjunction with SPT activation appeared highly prominent in the lumbar spinal cord in the experimental autoimmune encephalomyelitis (EAE) rats, the widely used animal model for MS, as we reported^\[[@R17]\]^. Hence, we have proposed that SPT activation plays a major role in cytokine mediated ceramide-sphingosine accumulation in EAE animals. New investigational drugs are always being examined to assess their effectiveness in the treatment of MS. Some new investigational therapeutics are immunomodulators such as fingolimod, laquinimod, teriflunomide, dimethyl fumarate, and cladribine that provide multiple options for treatment of MS patients. Fingolimod (or FTY720), which is an immunomodulator, as stated above, modulates ceramide metabolism and it has been introduced as a potent agent for MS therapy because its inhibitory effect on ceramide biosynthesis via ceramide synthase inhibition has clearly been demonstrated^\[[@R39],\ [@R40]\]^. Although FTY720 is a known sphingosine-1-phosphate (S1P) receptor antagonist, its role in sphingosine/ceramide regulation via S1P metabolic antagonism has not yet been examined. Since myriocin is the base structure of FTY720 (which is a myriocin derivative), we have hypothesized that FTY720 will inhibit ceramide generation (at least partly) after TNFα stimulation in a similar fashion. As we reported^\[[@R17]\]^, our data appeared in agreement with our hypothesis; since FTY720 exposure of human oligodendroglioma (HOG) cells counteracted the TNFα mediated lipid alteration by reducing ceramide biosynthesis^\[[@R17]\]^ and prevented cell death, as determined by fluorescent assisted cell sorting. However, the mechanism of ceramide inhibition by FTY720 differs from that of myriocin mediated SPT inhibition^\[[@R40]\]^. Myriocin blocks ceramide biosynthesis by inhibiting the SPT activation while FTY720 is more specific for inhibition of ceramide synthase ([Figure 1](#F1){ref-type="fig"}). Specifically, FTY720 is a competitive inhibitor for ceramide synthase 2^\[[@R40]\]^ and thus prevents cell death in oligodendrocytes. In fact, our studies indicate that myriocin offers more comprehensive protection than FTY720 to oligodendrocytes from cytokine-mediated apoptosis in cultured HOG cells^\[[@R17]\]^.

Our study strongly implies that sphingosine, in addition to ceramide, is a plausible secondary mediator of signal transduction for apoptosis in oligodendrocytes leading to demyelination in MS tissues and EAE animals^\[[@R17]\]^. Although our study specifically described the effect of TNFα and IFNγ in stimulating ceramide biosynthesis (\> 70%) via SPT activation leading to sphingosine accumulation^\[[@R17]\]^, an alternative way of ceramide generation (salvage pathway) via sphingomyelinase activation^\[[@R25]\]^ has not been ruled out. Such mechanism may also be active in sphingosine accumulation in addition to our proposed ceramide biosynthesis pathway.

It is noteworthy that our prime objective is to elucidate the ceramide/sphingosine generation in MS tissues, and we have discussed this aspect in detail with the emphasis on SPT mediated ceramide generation^\[[@R17]\]^. Clinical trials using TNFα antagonist (Lenercept) led to negative effects in MS^\[[@R41]\]^. A wide variety of inflammatory cytokines, which are released in MS, may exert an enormous devastation due to their collaborative or synergistic actions^\[[@R42]\]^. We believe that besides TNFα, stimulation of other cytokines (such as IL-1 and IFNγ) may alter metabolic property and actively degenerate oligodendrocytes and neurons triggering demyelination. Also, the strength or efficacy of the inhibitor is an important factor in preventing cell death. Based on our studies, we strongly suggest that a better approach is prevention or down regulation of the pro-inflammatory cytokine generation than an attempt to block its deleterious action, and this concept may lead to a new direction in MS research. Moreover, there are many known investigations for MS therapy using a wide variety of potentially targeted drugs ([Table 1](#T1){ref-type="table"}) but drugs that preferentially target to block the ceramide biosynthesis in MS have not yet been examined.

Ceramide biosynthesis as a potential therapeutic target for protection of oligodendrocytes in MS {#S3}
================================================================================================

We have demonstrated that sphingolipid metabolism has been altered in MS lesion as well as in NAWM. Alterations in sphingolipid metabolism in MS lesion and NAWM should be considered as an important observation. In spinal cords from EAE rats, ceramide production was transiently elevated followed by upregulation of levels of sphingosine and psychosine^\[[@R17]\]^. Furthermore, we have for the first time demonstrated an increase in ceramide and sphingosine in EAE tissues along with SPT activation and also concerted actions of TNFα and IFNγ causing sphingosine accumulation for oligodendrocyte cell death^\[[@R17]\]^. Thus, our results appeared in well agreement with previous publications that reported cytokine mediated *de novo* biosynthesis of ceramide^\[[@R43]\]^ in other cells leading to sphingosine elevation^\[[@R22],\ [@R44]\]^. Treating the cells with myriocin (and FTY720) largely encountered the cytokine mediated aberrant sphingolipid metabolism and prevented the oligodendrocyte cell death. Hence, our findings may lead to development of novel therapeutic approaches for the treatment of devastating demyelinating diseases by targeting the ceramide biosynthetic pathway. By controlling the pro-inflammatory response and encountering the cytotoxic lipid components, MS therapy may provide highly desirable positive consequences on neuro-repair and regeneration of myelinating oligodendrocytes; however, this hypothesis has not yet been tested in MS.

Conclusions {#S4}
===========

Although no single cause has yet been established for the pathogenesis in MS, it is evident that immunological dysfunction (autoimmunity) is the most common phenomenon that leads to release of a wide variety of cytokines, some of which have deleterious effects on lipid/protein metabolism. Clinical trials using TNFα antagonist (Lenercept) showed negative effects in MS^\[[@R41]\]^. A wide variety of pro-inflammatory cytokines^\[[@R45]\]^, which are released in MS tissue, may exert an enormous devastation due to their synergistic actions. Besides TNFα, stimulation of other cytokines (such as IL-1 and IFNγ) may alter lipid metabolism and thereby heavily contribute to degeneration of both oligodendrocytes and neurons. We have examined the mechanism of accumulation of sphingosine, which is a well-known toxic sphingolipid, in MS brain and the accumulation of sphingosine happens due to intermittent ceramide production via SPT activation. More research may be needed for the innovation of non-toxic drugs, which are capable of interrupting ceramide production by blocking SPT activation. Inhibition of ceramide production together with the use of immuno-suppressants may serve a sound basis for prospective MS therapy in the future. Currently available therapies and research activities are directed only to a specific site of pathogenesis while the cause of MS is far more complex. Thorough and intensive collaborative efforts involving national and international investigators may be warranted to reveal the major underlying mechanisms of pathogenesis of this devastating disease that may be targeted for long-term protection and, perhaps, an ultimate cure.
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A list of drugs that are currently being used for MS therapy

  Drugs/Trials                                      Plausible target                                                               Funding by
  ------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------
  Aspirin                                           Permeabilization to improve fatigue                                            NMSS
  Axona®                                            Improve cognitive function                                                     NMSS
  Estriol + Glatiramer acetate                      Control disease course                                                         NMSS
  Helminth (harmless parasitic worms)               Immunomodulation to reduce disease                                             NMSS
  Lipoic acid (antioxidant)                         Repair optic nerve injury                                                      NMSS
  Phenytoin (epilepsy drug)                         Prevent optic nerve injury                                                     NMSS
  Vitamin D + Glatiramer acetate                    Reduce disease activity                                                        NMSS
  The MS-SMART trial                                Three therapies with nerve-protecting properties in secondary-progressive MS   NMSS
  SPRINT-MS, Ibudilast (MN-166, MediciNova, Inc.)   Anti-inflammatory agent                                                        NMSS, Cleveland Clinic Foundation, and NeuroNEXT Network (a trial initiative of the NIH)
  Oxcarbazepine                                     Neuroprotective effects in secondary-progressive MS                            NMSS

NMSS, Multiple Sclerosis Society
